Q1 2023 Results

Company overview Financial review Conclusions Appendix References GROWTH Cosentyx® HS demonstrated durable efficacy, sustained up to 1 year Cosentyx® HS unmet need Lesions and abscesses in sensitive areas of the body ~97% patients suffer from pain¹ ~95% eligible patients not on biologic² ~50% biologic treated patients lose response³ Cosentyx opportunity ~400k addressable patients in US and EU4 Cosentyx Ph3 data** Durable efficacy sustained to 1 year Patients achieving AN50 (%) 80 70 60 56.2 Placebo SECQ2W Placebo SECQ4W SECQ4W 53.3 SECQ2W 39.7 30 Placebo 0 T 0 2 4 8 12 16 18 20 24 28 32 36 Week 40 44 48 52 Safety consistent with well-established* profile 7,5 Well tolerated Infrequent SAES Candidiasis uncommon³ 70.6 70.5 O 67.6 63.9 >70% with at least a 50% reduction in total abscess & inflammatory nodule count5 ≥70% flare free5 >65% with pain relief Fast and lasting QoL improvement5 Low immunogenicity See page 94 for references 1-8. HS hidradenitis suppurativa. QoL quality of life. SAE - serious adverse event. *Refers to approved indications. **HS indication currently under regulatory review. 14 Investor Relations | Q1 2023 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation